U.S. Contrast Media Market Size & Outlook, 2023-2030
U.S. contrast media market, 2018-2030 (US$M)
Related Markets
U.S. contrast media market highlights
- The U.S. contrast media market generated a revenue of USD 2,194.3 million in 2023 and is expected to reach USD 3,666.0 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, x-ray/computed tomography was the largest revenue generating modality in 2023.
- Ultrasound is the most lucrative modality segment registering the fastest growth during the forecast period.
Contrast media market data book summary
| Market revenue in 2023 | USD 2,194.3 million |
| Market revenue in 2030 | USD 3,666.0 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | X-ray/computed tomography |
| Fastest growing segment | Ultrasound |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ultrasound, Magnetic Resonance Imaging, X-ray/Computed Tomography |
| Key market players worldwide | Bayer AG, GE Aerospace, Guerbet, Bracco, Lantheus Holdings Inc, Imax Corp, Nano Therapeutics, Trivitron Healthcare |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.9% of the global contrast media market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. contrast media market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 3,666.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Contrast Media Market Scope
Contrast Media Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. contrast media market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to contrast media market will help companies and investors design strategic landscapes.
X-ray/computed tomography was the largest segment with a revenue share of 65.04% in 2023. Horizon Databook has segmented the U.S. contrast media market based on ultrasound, magnetic resonance imaging, x-ray/computed tomography covering the revenue growth of each sub-segment from 2018 to 2030.
In recent years, an increase in the use of diagnostic imaging tests has led to a rise in adoption of contrast agents. The presence of major market players in the country and various strategic initiatives undertaken by them are expected to contribute to market growth.
For instance, in June 2023, Bayer revealed that its iodine-based contrast agent, Ultravist (iopromide)-300, -370, secured approval from the U.S. FDA for use in CEM. This milestone designates it as the sole contrast agent sanctioned for this purpose. The product is applicable for visualizing suspected or known breast lesions in adult patients, serving as an adjunct to mammography and/or ultrasound examinations.
Furthermore, in September 2022, the U.S. FDA approved Gadopiclenol, a Magnetic Resonance Imaging (MRI) contrast agent that offers high relaxivity and reduced dosing of gadolinium for adults and pediatric patients aged 2 years & above. Gadopiclenol is a macrocyclic Gadolinium-based Contrast Agent (GBCA) that aids in diagnosing lesions with abnormal vascularity in the brain, spine, abdomen, and other areas of the body.
Reasons to subscribe to U.S. contrast media market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. contrast media market databook
-
Our clientele includes a mix of contrast media market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. contrast media market , including forecasts for subscribers. This country databook contains high-level insights into U.S. contrast media market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. contrast media market size, by modality, 2018-2030 (US$M)
U.S. Contrast Media Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
